ClinicalTrials.gg
CompletedNCT01127750Updated Feb 23, 2017

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

A Phase 3 interventional study of FTY720 in Relapsing Multiple Sclerosis, sponsored by Novartis. Completed at 290 sites in 23 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-02-23.

Sponsored by Novartis · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,417
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 34 studies testing fingolimod in Multiple Sclerosis — 2 open to participants now, 4 under way, 3 of them phase 3. fingolimod · Multiple Sclerosis.

Enrollment
3rd of 34
2,417 · median 167
Started
2010
with 3 others
Phase 3
12 of 34
1 open now
Registered
9th of 34
by date
Lead sponsor
10 of 34
Novartis

Among the 34 studies testing fingolimod in Multiple Sclerosis, this one is the 3rd largest by enrollment, is one of 4 that started in 2010, is one of 12 in phase 3, and was the 9th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

2 of the 34 studies testing fingolimod in Multiple Sclerosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fingolimod

fingolimod: first FDA approval 2010 (GILENYA), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies testing fingolimod in Multiple Sclerosis, or all of them as a file.
02

Study summary

This study will assess tolerability and safety and health outcomes in relapsing MS patients taking FTY720.

03

Conditions studied

  • Relapsing Multiple Sclerosis

Browse trials for

Keywords

  • Relapsing multiple sclerosis
  • MS
  • safety
  • tolerability
  • health outcomes
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-65 years of age, must have relapsing MS

Exclusion criteria

Exclusion Criteria:

  • Patients with a type of MS that is not relapsing
  • Patients with history of chronic immune disease
  • Patients with a history of certain cancers
  • Diabetic patients with certain eye disorders
  • Patients who are on certain medications or heart medications
  • Patients with certain heart conditions
  • Patients with certain lung conditions

Other protocol-defined inclusion/exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
2,417 participants (actual)

Study arms

  • Experimental
    FTY720

    Drug: FTY720

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate the safety and tolerability profile of FTY720 in patients with relapsing forms of MS

    Time frame: 4 months

Secondary outcomes

  1. Incidence of macular edema

    Time frame: 4 months

  2. Incidence of bradyarrhythmic electrocardiograms (ECGs)

    Time frame: 4 months

  3. Patient reported outcomes indices in multiple sclerosis (PRIMUS), short form health survey-12, and treatment satisfaction questionnaire for medication (TSQM-9)

    Time frame: 4 months

07

Study locations

290 sites
  • Novartis Investigative Site
    Box Hill, 3128, Australia
  • Novartis Investigative Site
    Heidelberg, 3084, Australia
  • Novartis Investigative Site
    Kogarah, 2217, Australia
  • Novartis Investigative Site
    Liverpool, 2170, Australia
  • Novartis Investigative Site
    Woodville South, 5011, Australia
  • Novartis Investigational Site
    Linz, A-4020, Austria
  • Novartis Investigational Site
    Vienna, 1010, Austria
  • Novartis Investigational Site
    Vienna, 1090, Austria
  • Novartis Investigational Site
    Brugge, 8000, Belgium
  • Novartis Investigational Site
    Bruxelles, 1070, Belgium
  • Novartis Investigational Site
    Bruxelles, 1200, Belgium
  • Novartis Investigational Site
    Charleroi, 6000, Belgium
  • Novartis Investigational Site
    Leuven, 3000, Belgium
  • Novartis Investigational Site
    Melsbroek, 1820, Belgium
  • Novartis Investigational Site
    Overpelt, 3900, Belgium
  • Novartis Investigational Site
    Sijsele, 8340, Belgium
  • Novartis Investigational Site
    Tinlot, 4557, Belgium
  • Novartis Investigational Site
    Wilrijk, 2610, Belgium
  • Novartis Investigational Site
    Montreal, H2L 4M1, Canada
  • Novartis Investigational Site
    Quebec, G1J 1Z4, Canada
  • Novartis Investigational Site
    Victoria, V8R 1J8, Canada
  • Novartis Investigational Site
    Praha 2, 128 02, Czech Republic
  • Novartis Investigational Site
    Teplice, 415 29, Czech Republic
  • Novartis Investigational Site
    Copenhagen, 2100, Denmark
  • Novartis Investigational Site
    Århus, DK-8000, Denmark
  • Novartis Investigational Site
    Helsinki, 00100, Finland
  • Novartis Investigational Site
    Turku, 20520, Finland
  • Novartis Investigational Site
    Aachen, 52062, Germany
  • Novartis Investigative Site
    Aachen, 52062, Germany
  • Novartis Investigational Site
    Aalen, 73430, Germany
  • Novartis Investigational Site
    Abensberg, 93326, Germany
  • Novartis Investigational Site
    Achim, 28832, Germany
  • Novartis Investigational Site
    Alzenau, 63755, Germany
  • Novartis Investigational Site
    Aschaffenburg, 63739, Germany
  • Novartis Investigational Site
    Attenberg, 04600, Germany
  • Novartis Investigational Site
    Augsburg, 86156, Germany
  • Novartis Investigational Site
    Bad Honnef, 53604, Germany
  • Novartis Investigational Site
    Bad Krozingen, 79189, Germany
  • Novartis Investigative Site
    Bad Mergentheim, 97980, Germany
  • Novartis Investigational Site
    Bad Neustadt / Saale, 97616, Germany
  • Novartis Investigational Site
    Bamberg, 96047, Germany
  • Novartis Investigational Site
    Bamberg, 96049, Germany
  • Novartis Investigative Site
    Bayreuth, 95445, Germany
  • Novartis Investigative Site
    Berlin, 10117, Germany
  • Novartis Investigative Site
    Berlin, 10178, Germany
  • Novartis Investigative Site
    Berlin, 10625, Germany
  • Novartis Investigative Site
    Berlin, 10713, Germany
  • Novartis Investigative Site
    Berlin, 10785, Germany
  • Novartis Investigative Site
    Berlin, 10961, Germany
  • Novartis Investigative Site
    Berlin, 12103, Germany
  • Novartis Investigative Site
    Berlin, 12163, Germany
  • Novartis Investigative Site
    Berlin, 12351, Germany
  • Novarris Investigative Site
    Berlin, 13088, Germany
  • Novartis Investigative Site
    Berlin, 13347, Germany
  • Novartis Investigative Site
    Berlin, 13439, Germany
  • Novartis Investigative Site
    Berlin, 13507, Germany
  • Novartis Investigative Site
    Berlin, 14163, Germany
  • Novartis Investigative Site
    Bielefeld, 33602, Germany
  • Novartis Investigative Site
    Bielefeld, 33617, Germany
  • Novartis Investigative Site
    Bielefeld, 33647, Germany
  • Novartis Investigative Site
    Boblingen, 71034, Germany
  • Novartis Investigational Site
    Bochum, 44787, Germany
  • Novartis Investigative Site
    Bochum, 44789, Germany
  • Novartis Investigational Site
    Bochum, 44791, Germany
  • Novaratis Investigative Site
    Bochum, 44892, Germany
  • Novartis Investigational Site
    Bogen, 94327, Germany
  • Novartis Investigative Site
    Bonn, 53105, Germany
  • Novartis Investigative Site
    Bonn, 53117, Germany
  • Novartis Investigational Site
    Braunschweig, 38126, Germany
  • Novartis Investigational Site
    Buchholz, 21244, Germany
  • Novartis Investigational Site
    Chemnitz, 09117, Germany
  • Novartis Investigational Site
    Dillingen, 89407, Germany
  • Novartis Investigative Site
    Dresden, 01307, Germany
  • Novartis Investigative Site
    Düsseldorf, 40211, Germany
  • Novartis Investigational Site
    Eisenach, 99817, Germany
  • Novartis Investigative Site
    Emden, 26721, Germany
  • Novartis Investigational Site
    Emmendingen, 79312, Germany
  • Novartis Investigative Site
    Erbach, 64711, Germany
  • Novartis Investigational Site
    Erfurt, 99089, Germany
  • Novartis Investigational Site
    Erlangen, 91054, Germany
  • Novartis Investigative Site
    Essen, 103949, Germany
  • Novartis Investigational Site
    Essen, 45131, Germany
  • Novartis Investigative Site
    Essen, 45138, Germany
  • Novartis Investigational Site
    Frankfurt, 60488, Germany
  • Novartis Investigational Site
    Frankfurt, 60528, Germany
  • Novartis Investigative Site
    Freiburg, 79106, Germany
  • Novartis Investigational Site
    Greifswald, 17487, Germany
  • Novartis Investigational Site
    Grevenbroich, 41515, Germany
  • Novartis Investigative Site
    Hamburg, 20099, Germany
  • Novartis Investigative Site
    Hamburg, 20249, Germany
  • Novartis Investigative Site
    Hamburg, 20354, Germany
  • Novartis Investigative Site
    Hamburg, 22083, Germany
  • Novartis Investigational Site
    Hamburg, 22087, Germany
  • Novartis Investigative Site
    Hamburg, 22179, Germany
  • Novartis Investigational Site
    Hamburg, 22291, Germany
  • Novartis Investigative Site
    Hamburg, 22297, Germany
  • Novartis Investigative Site
    Hamburg, 22523, Germany
  • Novartis Investigative Site
    Hannover, 30161, Germany
  • Novartis Investigative Site
    Hannover, 30559, Germany
  • Novartis Investigative Site
    Hannover, 30625, Germany

Showing the first 100 of 290 sites across 23 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Gold R, Comi G, Palace J, Siever A, Gottschalk R, Bijarnia M, von Rosenstiel P, Tomic D, Kappos L; FIRST Study Investigators. Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study. J Neurol. 2014 Feb;261(2):267-76. doi: 10.1007/s00415-013-7115-8. Epub 2013 Nov 13. PubMed 24221641 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2010, a primary completion of Oct 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2010
First posted
May 21, 2010
Start
May 2010
Primary completionActual
Oct 2011
CompletionActual
Oct 2011
Last update
Feb 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01127750
Lead sponsor
Novartis
Responsible party
Sponsor
First posted
May 21, 2010
Start date
May 2010
Primary completion
Oct 2011
Completion
Oct 2011
Last update
Feb 23, 2017

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fingolimod

Start the discussion